ESR1 and breast carcinoma: In MDM2 SNP309 estrogen receptor positive (ER+) breast cancer cell lines treated with estrogen, there was an increase in MDM2-C expression in the nucleus and cytoplasm, but this did not lead to degradation or decreased p53 levels [17].